Is plasma caveolin-1 level a prognostic biomarker in metastatic pancreatic cancer?
Background/Aims: To evaluate the prognostic significance of plasma caveolin (CAV)-1 and its association with survival and treatment response rates in metastatic pancreatic cancer (MPC). Patients and Methods: Plasma samples were prospectively collected from 41 patients with newly diagnosed MPC. Moreo...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2017-01-01
|
| Series: | The Saudi Journal of Gastroenterology |
| Subjects: | |
| Online Access: | http://www.saudijgastro.com/article.asp?issn=1319-3767;year=2017;volume=23;issue=3;spage=183;epage=189;aulast=Demirci |
| _version_ | 1818988376165974016 |
|---|---|
| author | Nebi S Demirci Mutlu Dogan Gokmen U Erdem Sabite Kacar Turan Turhan Saadettin Kilickap Lutfi C Cigirgan Ertugrul Kayacetin Yakup Bozkaya Nurullah Zengin |
| author_facet | Nebi S Demirci Mutlu Dogan Gokmen U Erdem Sabite Kacar Turan Turhan Saadettin Kilickap Lutfi C Cigirgan Ertugrul Kayacetin Yakup Bozkaya Nurullah Zengin |
| author_sort | Nebi S Demirci |
| collection | DOAJ |
| description | Background/Aims: To evaluate the prognostic significance of plasma caveolin (CAV)-1 and its association with survival and treatment response rates in metastatic pancreatic cancer (MPC).
Patients and Methods: Plasma samples were prospectively collected from 41 patients with newly diagnosed MPC. Moreover, plasma samples were collected from 48 patients with chronic pancreatitis and 41 healthy individuals (control groups) for assessing Cav-1 levels. Plasma Cav-1 levels were evaluated at baseline and after three cycles of chemotherapy in the patients with MPC.
Results: The median Cav-1 level was 13.8 ng/mL for the patients with MPC and 12.2 ng/mL for healthy individuals (P = 0.009). The Cav-1 cut-off level was calculated as 11.6 ng/mL by using the receiver operating characteristic curve. The median overall survival and progression-free survival rates were 5 and 2.4 months, respectively, for participants with a high basal plasma Cav-1 level; the corresponding values were 10.5 and 9.4 months for participants with a low plasma Cav-1 level (P = 0.011 and P= 0.003, respectively). Of the 41 patients with MPC, 23 completed at least three cycles of chemotherapy. The median Cav-1 level was 13 ng/mL for post-treatment MPC (r2: 0.917; P= 0.001). High basal plasma caveolin-1 level have continued to remain at high levels even after chemotherapy, showing a trend toward worse response rates (P = 0.086).
Conclusion: High basal plasma Cav-1 levels seem to be associated with poor survival and tend to yield worse therapeutic outcomes in patients with MPC. This study is the first to evaluate the prognostic significance of plasma Cav-1 levels as a prognostic factor in patients with MPC. However, larger prospective clinical trials are warranted. |
| first_indexed | 2024-12-20T19:21:36Z |
| format | Article |
| id | doaj.art-62a5ddbc0e53487fb9fd1b53695fcb15 |
| institution | Directory Open Access Journal |
| issn | 1319-3767 1998-4049 |
| language | English |
| last_indexed | 2024-12-20T19:21:36Z |
| publishDate | 2017-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | The Saudi Journal of Gastroenterology |
| spelling | doaj.art-62a5ddbc0e53487fb9fd1b53695fcb152022-12-21T19:28:59ZengWolters Kluwer Medknow PublicationsThe Saudi Journal of Gastroenterology1319-37671998-40492017-01-0123318318910.4103/sjg.SJG_483_16Is plasma caveolin-1 level a prognostic biomarker in metastatic pancreatic cancer?Nebi S DemirciMutlu DoganGokmen U ErdemSabite KacarTuran TurhanSaadettin KilickapLutfi C CigirganErtugrul KayacetinYakup BozkayaNurullah ZenginBackground/Aims: To evaluate the prognostic significance of plasma caveolin (CAV)-1 and its association with survival and treatment response rates in metastatic pancreatic cancer (MPC). Patients and Methods: Plasma samples were prospectively collected from 41 patients with newly diagnosed MPC. Moreover, plasma samples were collected from 48 patients with chronic pancreatitis and 41 healthy individuals (control groups) for assessing Cav-1 levels. Plasma Cav-1 levels were evaluated at baseline and after three cycles of chemotherapy in the patients with MPC. Results: The median Cav-1 level was 13.8 ng/mL for the patients with MPC and 12.2 ng/mL for healthy individuals (P = 0.009). The Cav-1 cut-off level was calculated as 11.6 ng/mL by using the receiver operating characteristic curve. The median overall survival and progression-free survival rates were 5 and 2.4 months, respectively, for participants with a high basal plasma Cav-1 level; the corresponding values were 10.5 and 9.4 months for participants with a low plasma Cav-1 level (P = 0.011 and P= 0.003, respectively). Of the 41 patients with MPC, 23 completed at least three cycles of chemotherapy. The median Cav-1 level was 13 ng/mL for post-treatment MPC (r2: 0.917; P= 0.001). High basal plasma caveolin-1 level have continued to remain at high levels even after chemotherapy, showing a trend toward worse response rates (P = 0.086). Conclusion: High basal plasma Cav-1 levels seem to be associated with poor survival and tend to yield worse therapeutic outcomes in patients with MPC. This study is the first to evaluate the prognostic significance of plasma Cav-1 levels as a prognostic factor in patients with MPC. However, larger prospective clinical trials are warranted.http://www.saudijgastro.com/article.asp?issn=1319-3767;year=2017;volume=23;issue=3;spage=183;epage=189;aulast=DemirciCaveolin-1cisplatingemcitabinepancreatic cancerprognosisresistancetreatment response |
| spellingShingle | Nebi S Demirci Mutlu Dogan Gokmen U Erdem Sabite Kacar Turan Turhan Saadettin Kilickap Lutfi C Cigirgan Ertugrul Kayacetin Yakup Bozkaya Nurullah Zengin Is plasma caveolin-1 level a prognostic biomarker in metastatic pancreatic cancer? The Saudi Journal of Gastroenterology Caveolin-1 cisplatin gemcitabine pancreatic cancer prognosis resistance treatment response |
| title | Is plasma caveolin-1 level a prognostic biomarker in metastatic pancreatic cancer? |
| title_full | Is plasma caveolin-1 level a prognostic biomarker in metastatic pancreatic cancer? |
| title_fullStr | Is plasma caveolin-1 level a prognostic biomarker in metastatic pancreatic cancer? |
| title_full_unstemmed | Is plasma caveolin-1 level a prognostic biomarker in metastatic pancreatic cancer? |
| title_short | Is plasma caveolin-1 level a prognostic biomarker in metastatic pancreatic cancer? |
| title_sort | is plasma caveolin 1 level a prognostic biomarker in metastatic pancreatic cancer |
| topic | Caveolin-1 cisplatin gemcitabine pancreatic cancer prognosis resistance treatment response |
| url | http://www.saudijgastro.com/article.asp?issn=1319-3767;year=2017;volume=23;issue=3;spage=183;epage=189;aulast=Demirci |
| work_keys_str_mv | AT nebisdemirci isplasmacaveolin1levelaprognosticbiomarkerinmetastaticpancreaticcancer AT mutludogan isplasmacaveolin1levelaprognosticbiomarkerinmetastaticpancreaticcancer AT gokmenuerdem isplasmacaveolin1levelaprognosticbiomarkerinmetastaticpancreaticcancer AT sabitekacar isplasmacaveolin1levelaprognosticbiomarkerinmetastaticpancreaticcancer AT turanturhan isplasmacaveolin1levelaprognosticbiomarkerinmetastaticpancreaticcancer AT saadettinkilickap isplasmacaveolin1levelaprognosticbiomarkerinmetastaticpancreaticcancer AT lutficcigirgan isplasmacaveolin1levelaprognosticbiomarkerinmetastaticpancreaticcancer AT ertugrulkayacetin isplasmacaveolin1levelaprognosticbiomarkerinmetastaticpancreaticcancer AT yakupbozkaya isplasmacaveolin1levelaprognosticbiomarkerinmetastaticpancreaticcancer AT nurullahzengin isplasmacaveolin1levelaprognosticbiomarkerinmetastaticpancreaticcancer |